Kantoko Raises $3.5M Seed for ADHD Digital Health Platform

Kantoko, a digital health platform addressing the significant access challenges for Attention Deficit Hyperactivity Disorder (ADHD) care, has successfully closed a $3.5 million Seed funding round. The investment was spearheaded by Side Stage Venture and Tenmile, with participation from notable angel investors, including the founders of edtech firm Go1. This capital infusion is earmarked to bolster Kantoko's clinical network, advance its proprietary technology, and broaden its reach across Australia.

The venture is the brainchild of serial entrepreneur Zac Altman, who brings a track record of successful exits, including his previous company LoungeBuddy, which was acquired by American Express. Altman's personal experience with ADHD, including navigating the complex and often lengthy re-diagnosis process in Australia, served as the primary catalyst for founding Kantoko in 2023. He aims to dismantle the systemic barriers that prevent an estimated 75% of Australian adults with ADHD from receiving timely diagnosis and treatment.

Altman articulated the driving force behind the company: "I had no choice but to build this company. I went through re-diagnosis as an adult and saw how broken the system is at every step. Nobody should have to fight that hard for care that changes their life, so we built the system that should have existed all along." Kantoko's model focuses on delivering clinical-grade assessment, treatment, and ongoing support through a national network of healthcare professionals, leveraging technology to expedite the process from months to mere weeks, at a reduced cost compared to traditional in-person clinics.

The ADHD market presents a substantial opportunity, with global prevalence estimated at one in 20 individuals. However, access to specialized care remains a critical bottleneck. Ben Grabiner, founding partner at Side Stage Venture, commented on the market's unmet needs: "Scaling high-quality care for them is one of the biggest unsolved problems in health." He further expressed confidence in Altman's vision, stating, "We’re excited to back Zac – a deeply experienced entrepreneur on a personal mission to fix a broken system and transform how ADHD care is delivered."

Kantoko's innovative approach offers a GP-led, continuous care model designed around patient needs, a paradigm shift from the often-frustrating waiting room experience. This patient-centric methodology is intended to serve as a blueprint for managing chronic conditions more effectively across the healthcare spectrum. The recent funding will be instrumental in scaling this model and extending its impact to a larger patient population, addressing what Altman identifies as the widest access gap in chronic condition management.

The broader health tech sector continues to see significant investor interest, particularly in solutions that enhance accessibility and affordability. Companies focusing on chronic disease management and mental health services have attracted substantial capital, reflecting a growing demand for digital-first healthcare solutions. Kantoko's success in securing this Seed round underscores the market's recognition of the urgent need for improved ADHD care pathways and the potential for technology-driven interventions.